دورية أكاديمية
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
| العنوان: | Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial |
|---|---|
| المؤلفون: | Puig, Noemi, Hernandez, Miguel T., Rosiñol, Laura, Gonzalez, Maria-Esther, Arriba, Felipe de, Oriol, Albert, Gonzalez-Calle, David, Escalante, Fernando, Rubia, Javier de la, Gironella, Mercedes, Ríos, Rafael, García-Sánchez, Ricarda, Arguiñano, José M., Alegre, Adrian, Martín, Jesús, Gutiérrez, Norma Carmen, Calasanz, Mª Jose, Martín, María L., Couto, María del Carmen, Casanova, María, Arnao‐Herráiz, Mario, Pérez-Persona, Ernesto, Garzón, Sebastián, González, Marta S., Martín-Sánchez, Guillermo, Ocio, Enrique M., Coleman, Morton, Encinas, Cristina, Vale, Ana M., Teruel, Ana-Isabel, Cortés-Rodríguez, María, Paiva, Bruno, Cedena, Maria-Teresa, San Miguel, Jesús F., Lahuerta, Juan José, Bladé, Joan, Niesvizky, Ruben, Mateos, Maria Victoria |
| بيانات النشر: | Springer Nature |
| سنة النشر: | 2021 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Myeloma, Randomized controlled trials |
| الوصف: | © The Author(s) 2021. ; Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or without clarithromycin until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). With a median follow-up of 19 months (range, 0–54), no significant differences in the median PFS were observed between the two arms (C-Rd 23 months, Rd 29 months; HR 0.783, p = 0.14), despite a higher rate of complete response (CR) or better in the C-Rd group (22.6% vs 14.4%, p = 0.048). The most common G3–4 adverse events were neutropenia [12% vs 19%] and infections [30% vs 25%], similar between the two arms; however, the percentage of toxic deaths was higher in the C-Rd group (36/50 [72%] vs 22/40 [55%], p = 0.09). The addition of clarithromycin to Rd in untreated transplant ineligible MM patients does not improve PFS despite increasing the ≥CR rate due to the higher number of toxic deaths in the C-Rd arm. Side effects related to overexposure to steroids due to its delayed clearance induced by clarithromycin in this elderly population could explain these results. The trial was registered in clinicaltrials.gov with the name GEM-CLARIDEX: Ld vs BiRd and with the following identifier NCT02575144. The full trial protocol can be accessed from ClinicalTrials.gov. This study received financial support from BMS/Celgene. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 2044-5385 |
| العلاقة: | Publisher's version; http://dx.doi.org/10.1038/s41408-021-00490-8Test; Sí; Blood Cancer Journal 11 (2021); http://hdl.handle.net/10261/261640Test |
| DOI: | 10.1038/s41408-021-00490-8 |
| الإتاحة: | https://doi.org/10.1038/s41408-021-00490-8Test http://hdl.handle.net/10261/261640Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.C9AD36A6 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20445385 |
|---|---|
| DOI: | 10.1038/s41408-021-00490-8 |